Applicability of magnetic seeds for target lymph node biopsy after neoadjuvant chemotherapy in initially node-positive breast cancer patients: data from the AXSANA study

• Published in: Breast cancer research and treatment 2023-12, Vol.202 (3), p.497-504
• Main Authors: Hartmann, Steffi, Banys-Paluchowski, Maggie, Stickeler, Elmar, de Boniface, Jana, Gentilini, Oreste Davide, Kontos, Michalis, Seitz, Stephan, Kaltenecker, Gabriele, Wärnberg, Fredrik, Zetterlund, Linda Holmstrand, Kolberg, Hans-Christian, Fröhlich, Sarah, Kühn, Thorsten
• Format: Article
• Language: English
• Subjects: Adjuvant treatment; Biopsy; Breast cancer; Cancer; Cancer and Oncology; Cancer och onkologi; Cancer patients; Cancer research; Care and treatment; Chemotherapy; Clinical Trial; Lymph nodes; Lymphatic system; Lymphoid tissue; Magnetic resonance imaging; Magnetic seed; Medicin och hälsovetenskap; Medicine; Medicine & Public Health; Neoadjuvant chemotherapy; Oncology; Oncology, Experimental; Seeds; Target lymph node; Targeted axillary dissection
• ISSN: 0167-6806; 1573-7217; 1573-7217
• DOI: 10.1007/s10549-023-07100-0

Purpose Currently, various techniques are available to mark and selectively remove initially suspicious axillary lymph nodes (target lymph nodes, TLNs) in breast cancer patients receiving neoadjuvant chemotherapy (NACT). To date, limited data are available on whether the use of magnetic seeds (MS) is suitable for localizing TLNs. This study aimed to investigate the feasibility of MS in patients undergoing target lymph node biopsy (TLNB) or targeted axillary dissection (TAD) after NACT. Methods Prospective data from the ongoing multicentric AXSANA study were extracted from selected patients in whom the TLN had been marked with an MS before NACT and who were enrolled from June 2020 to June 2023. The endpoints of the analysis were the detection rate, the rate of lost markers, and the potential impairment on magnetic resonance imaging (MRI) assessment. Results In 187 patients from 27 study sites in seven countries, MS were placed into the TLN before NACT. In 151 of these, post-NACT surgery had been completed at the time of analysis. In 146 patients (96.0%), a TLN could successfully be detected. In three patients, the seed was removed but no lymphoid tissue was detected on histopathology. The rate of lost markers was 1.2% (2 out of 164 MS). In 15 out of 151 patients (9.9%), MRI assessment was reported to be compromised by MS placement. Conclusion MS show excellent applicability for TLNB/TAD when inserted before NACT with a high DR and a low rate of lost markers. Axillary MS can impair MRI assessment of the breast. Trial registration number NCT04373655 (date of registration May 4, 2020).